Great Lakes Advisors LLC Makes New $857,000 Investment in Kenvue Inc. $KVUE

Key Points

• Great Lakes Advisors LLC invested approximately $857,000 in Kenvue Inc., acquiring 35,720 shares in the first quarter.
• Kenvue reported a quarterly earnings per share of $0.29, exceeding the consensus estimate of $0.28, despite a 4% decline in revenue year-over-year.
• The company increased its dividend to $0.2075 per share, which corresponds to an annualized yield of 4.4%.

Great Lakes Advisors LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 35,720 shares of the company's stock, valued at approximately $857,000.

Several other large investors also recently added to or reduced their stakes in KVUE. Captrust Financial Advisors grew its position in Kenvue by 16.4% during the fourth quarter. Captrust Financial Advisors now owns 62,803 shares of the company's stock valued at $1,341,000 after buying an additional 8,826 shares during the period. Ensign Peak Advisors Inc grew its position in Kenvue by 9.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 169,137 shares of the company's stock valued at $3,611,000 after buying an additional 14,322 shares during the period. Janus Henderson Group PLC grew its position in Kenvue by 20.2% during the fourth quarter. Janus Henderson Group PLC now owns 263,969 shares of the company's stock valued at $5,640,000 after buying an additional 44,393 shares during the period. Nuveen Asset Management LLC grew its position in Kenvue by 13.1% during the fourth quarter. Nuveen Asset Management LLC now owns 10,360,001 shares of the company's stock valued at $221,186,000 after buying an additional 1,198,432 shares during the period. Finally, NorthRock Partners LLC grew its position in Kenvue by 149.5% during the fourth quarter. NorthRock Partners LLC now owns 29,421 shares of the company's stock valued at $628,000 after buying an additional 17,629 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 2.0%

KVUE stock opened at $18.84 on Friday. Kenvue Inc. has a 1-year low of $17.15 and a 1-year high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The company has a market capitalization of $36.16 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 2.65 and a beta of 0.83. The business has a 50 day simple moving average of $21.18 and a two-hundred day simple moving average of $22.27.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same period in the prior year, the company posted $0.32 EPS. The firm's revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date of this dividend was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio is presently 112.16%.

Analysts Set New Price Targets

KVUE has been the subject of several recent research reports. Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research report on Friday, August 8th. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Barclays decreased their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Tuesday, July 15th. UBS Group reduced their price objective on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. Finally, Bank of America reduced their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and a consensus price target of $24.21.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.